NRAS Mutations May Be Involved in the Pathogenesis of Cutaneous Rosai Dorfman Disease: A Pilot Study

doi:10.3390/biology10050396

CNU IR > Pharmacy and Science > Dept. of Cosmetic Science and institute of cosmetic science > Periodical Articles > Item 310902800/34432

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34432

Title:	NRAS Mutations May Be Involved in the Pathogenesis of Cutaneous Rosai Dorfman Disease: A Pilot Study
Authors:	Wu, Kuan-Jou Li, Shu-Hao Liao, Jia-Bin Chiou, Chien-Chun Wu, Chieh-Shan Chen, Chien-Chin
Contributors:	Kaohsiung Vet Gen Hosp, Dept Dermatol Chang Gung Mem Hosp, Dept Dermatol Natl Yang Ming Univ, Sch Med Kaohsiung Vet Gen Hosp, Dept Pathol & Lab Med Chia Yi Christian Hosp, Ditmanson Med Fdn, Dept Dermatol Kaohsiung Med Univ, Coll Med, Fac Med, Dept Dermatol Chia Yi Christian Hosp, Ditmanson Med Fdn, Dept Pathol Chia Nan Univ Pharm & Sci, Dept Cosmet Sci
Keywords:	skin Rosai8211 Dorfman genetic KRAS NRAS BRAF skin cancer biomarker
Date:	2021
Issue Date:	2023-11-11 11:52:28 (UTC+8)
Publisher:	MDPI
Abstract:	Background: Purely cutaneous Rosai-Dorfman disease (RDD) is a rare histiocytic proliferative disorder limited to the skin. To date, its pathogenesis remains unclear. Owing to recent findings of specific mutations in the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway in histiocytic proliferative disorders, it provides a novel perspective on the pathomechanism of cutaneous RDD. We aim to investigate the genomic mutations in MAPK/ERK pathway in cutaneous RDD. Methods: We retrospectively recruited all cases of cutaneous RDD from two hospitals in Taiwan from January 2010 to March 2020 with the clinicopathologic features, immunohistochemistry, and treatment. Mutations of neuroblastoma RAS viral oncogene homolog (NRAS), Kirsten rat sarcoma 2 viral oncogene homolog (KRAS), and v-raf murine sarcoma viral oncogene homolog B1 (BRAF) in MAPK/ERK pathway were investigated by the highly sensitive polymerase chain reaction with Sanger sequencing. Results: Seven patients with cutaneous RDD were recruited with nine biopsy specimens. The median age was 46 years (range: 17-62 years). Four of seven patients (57.1%) received tumor excision, while the other three chose oral and/or topical or intralesional steroids. NRAS mutation was detected in 4 of 7 cases (4/7; 51.7%), and NRAS A146T was the most common mutant point (n = 4/7), followed by NRAS G13S (n = 2/7). There is no KRAS or BRAF mutation detected. Conclusions: We report the NRAS mutation is common in cutaneous RDD, and NRAS A146T was the most frequent mutation in this cohort. Mutations in the NRAS gene can activate the RAS/MAPK signaling and have been reported to be associated with various cancers. It indicates that NRAS mutation in MAPK/ERK pathway may involve the pathogenesis of cutaneous RDD.
Relation:	BIOLOGY-BASEL, v.10, n.5, 396
Appears in Collections:	[Dept. of Cosmetic Science and institute of cosmetic science] Periodical Articles

Files in This Item:

File	Description	Size	Format
biology10050396.pdf		2191Kb	Adobe PDF	92	View/Open
index.html		0Kb	HTML	156	View/Open

Loading...